Christopher Goshgarian1, Philip B Gorelick2,3. 1. Mercy Health Hauenstein Neurosciences, 220 Cherry Street SE, Room H 3037, Grand Rapids, MI, 49503, USA. christopher.goshgarian@mercyhealth.com. 2. Mercy Health Hauenstein Neurosciences, 220 Cherry Street SE, Room H 3037, Grand Rapids, MI, 49503, USA. 3. Translational Science & Molecular Medicine, Michigan State University College of Human Medicine, East Lansing, MI, USA.
Abstract
PURPOSE OF REVIEW: The purpose of this review is to discuss the prevention of venous thromboembolism (VTE) in stroke patients. We discuss use of oral anticoagulation and other interventions for the prevention of VTE. A new class of medications, non-vitamin K antagonist oral anticoagulants (NOACs), have been successfully trialed for the prevention of VTE. We review the data and guidance statements for VTE prevention. RECENT FINDINGS: Warfarin and vitamin K antagonist drugs have been the mainstay of VTE prevention for decades. More recently, NOACs have become available for both stroke and systemic embolism prevention in nonvalvular atrial fibrillation and for VTE treatment or prevention. NOACs have been shown to be at least noninferior for VTE prevention and treatment when compared with warfarin, and have a good safety profile. Other approaches include use of graduated compression stockings, intermittent compression stockings, inferior vena cava filters, and heparins. Selection of the appropriate VTE prophylaxis in stroke patients is important to reduce associated morbidity and mortality.
PURPOSE OF REVIEW: The purpose of this review is to discuss the prevention of venous thromboembolism (VTE) in strokepatients. We discuss use of oral anticoagulation and other interventions for the prevention of VTE. A new class of medications, non-vitamin K antagonist oral anticoagulants (NOACs), have been successfully trialed for the prevention of VTE. We review the data and guidance statements for VTE prevention. RECENT FINDINGS:Warfarin and vitamin K antagonist drugs have been the mainstay of VTE prevention for decades. More recently, NOACs have become available for both stroke and systemic embolism prevention in nonvalvular atrial fibrillation and for VTE treatment or prevention. NOACs have been shown to be at least noninferior for VTE prevention and treatment when compared with warfarin, and have a good safety profile. Other approaches include use of graduated compression stockings, intermittent compression stockings, inferior vena cava filters, and heparins. Selection of the appropriate VTE prophylaxis in strokepatients is important to reduce associated morbidity and mortality.
Entities:
Keywords:
Deep vein thrombosis; Prevention; Stroke; Venous thromboembolism
Authors: Luis F Angel; Victor Tapson; Richard E Galgon; Marcos I Restrepo; John Kaufman Journal: J Vasc Interv Radiol Date: 2011-11 Impact factor: 3.464
Authors: Harry R Büller; Hervé Décousus; Michael A Grosso; Michele Mercuri; Saskia Middeldorp; Martin H Prins; Gary E Raskob; Sebastian M Schellong; Lee Schwocho; Annelise Segers; Minggao Shi; Peter Verhamme; Phil Wells Journal: N Engl J Med Date: 2013-08-31 Impact factor: 91.245
Authors: John A Kaufman; Thomas B Kinney; Michael B Streiff; Ronald F Sing; Mary C Proctor; Daniel Becker; Mark Cipolle; Anthony J Comerota; Steven F Millward; Frederick B Rogers; David Sacks; Anthony C Venbrux Journal: J Vasc Interv Radiol Date: 2006-03 Impact factor: 3.464
Authors: J Claude Hemphill; Steven M Greenberg; Craig S Anderson; Kyra Becker; Bernard R Bendok; Mary Cushman; Gordon L Fung; Joshua N Goldstein; R Loch Macdonald; Pamela H Mitchell; Phillip A Scott; Magdy H Selim; Daniel Woo Journal: Stroke Date: 2015-05-28 Impact factor: 7.914
Authors: Sam Schulman; Clive Kearon; Ajay K Kakkar; Patrick Mismetti; Sebastian Schellong; Henry Eriksson; David Baanstra; Janet Schnee; Samuel Z Goldhaber Journal: N Engl J Med Date: 2009-12-10 Impact factor: 91.245
Authors: Giancarlo Agnelli; Harry R Buller; Alexander Cohen; Madelyn Curto; Alexander S Gallus; Margot Johnson; Anthony Porcari; Gary E Raskob; Jeffrey I Weitz Journal: N Engl J Med Date: 2012-12-08 Impact factor: 91.245
Authors: David G Sherman; Gregory W Albers; Christopher Bladin; Cesare Fieschi; Alberto A Gabbai; Carlos S Kase; William O'Riordan; Graham F Pineo Journal: Lancet Date: 2007-04-21 Impact factor: 79.321